Global Information Lookup Global Information

Delandistrogene moxeparvovec information


Delandistrogene moxeparvovec
Clinical data
Trade namesElevidys
Other namesSRP-9001, delandistrogene moxeparvovec-rokl
License data
  • US DailyMed: Delandistrogene moxeparvovec
Routes of
administration
Intravenous
ATC code
  • M09AX15 (WHO)
Legal status
Legal status
  • US: ℞-only[1][2]
Identifiers
CAS Number
  • 2305040-16-6
DrugBank
  • DB16802
UNII
  • 2P6QV2ZE52
KEGG
  • D12633

Delandistrogene moxeparvovec, sold under the brand name Elevidys, is a recombinant gene therapy used for the treatment of Duchenne muscular dystrophy.[3] It is designed to deliver into the body a gene that leads to production of Elevidys micro-dystrophin that contains selected domains of the dystrophin protein present in normal muscle cells.[3] It is an adeno-associated virus vector-based gene therapy that is given by injection into a vein.[1]

The most commonly reported side effects include vomiting, nausea, acute liver injury, pyrexia (fever), and thrombocytopenia (abnormally low platelet count in the blood).[3]

Delandistrogene moxeparvovec was approved for medical use in the United States in June 2023.[3][4] It was developed by Sarepta Therapeutics and is manufactured by Catalent.[5]

  1. ^ a b "Elevidys- delandistrogene moxeparvovec-rokl kit". DailyMed. 22 June 2023. Retrieved 29 August 2023.
  2. ^ "Elevidys". U.S. Food and Drug Administration (FDA). 22 June 2023. Archived from the original on 5 July 2023. Retrieved 22 June 2023.
  3. ^ a b c d "FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy" (Press release). U.S. Food and Drug Administration (FDA). 22 June 2023. Retrieved 22 June 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Sarepta Therapeutics Announces FDA Approval of Elevidys, the First Gene Therapy to Treat Duchenne Muscular Dystrophy" (Press release). Sarepta Therapeutics. 22 June 2023. Retrieved 22 June 2023 – via Business Wire.
  5. ^ "Catalent inks deal to manufacture Sarepta's DMD gene therapy". Archived from the original on 17 February 2023. Retrieved 23 June 2023.

and 7 Related for: Delandistrogene moxeparvovec information

Request time (Page generated in 0.7775 seconds.)

Delandistrogene moxeparvovec

Last Update:

Delandistrogene moxeparvovec, sold under the brand name Elevidys, is a recombinant gene therapy used for the treatment of Duchenne muscular dystrophy....

Word Count : 486

Dystrophin

Last Update:

hypertrophy, this model may have limited uses for DMD studies.   Delandistrogene moxeparvovec - systemic gene transfer with rAAVrh74.MHCK7.micro-dystrophin...

Word Count : 2464

Catalent

Last Update:

Catalent partnered with Sarepta Therapeutics to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced gene therapy candidate for...

Word Count : 1822

Duchenne muscular dystrophy

Last Update:

and were published in 2010. An update was published in 2018. Delandistrogene moxeparvovec (Elevidys) is a gene therapy that in June 2023 received United...

Word Count : 6468

List of gene therapies

Last Update:

Ciltacabtagene autoleucel (Carvykti): treatment for multiple myeloma Delandistrogene moxeparvovec (Elevidys): treatment for Duchenne muscular dystrophy Elivaldogene...

Word Count : 792

ATC code M09

Last Update:

M09AX12 Viltolarsen M09AX13 Casimersen M09AX14 Givinostat M09AX15 Delandistrogene moxeparvovec QM09AX90 Equine stem cells QM09AX99 Combinations "ATC (Anatomical...

Word Count : 248

Gene therapy

Last Update:

vascular endothelial growth factor peripheral artery disease delandistrogene moxeparvovec Elevidys In vivo Catalent Duchenne muscular dystrophy 22 June...

Word Count : 17769

PDF Search Engine © AllGlobal.net